Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H19N3S.ClH |
| Molecular Weight | 321.868 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(CN1C2=CC=CC=C2SC3=CC=CN=C13)N(C)C
InChI
InChIKey=RQHCFTORMXCNGP-UHFFFAOYSA-N
InChI=1S/C16H19N3S.ClH/c1-12(18(2)3)11-19-13-7-4-5-8-14(13)20-15-9-6-10-17-16(15)19;/h4-10,12H,11H2,1-3H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H19N3S |
| Molecular Weight | 285.407 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.drugbank.ca/drugs/DB08802Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/isothipendyl.html | https://www.ncbi.nlm.nih.gov/pubmed/22677929 | https://www.ncbi.nlm.nih.gov/pubmed/13792589 | https://www.ncbi.nlm.nih.gov/pubmed/14157559
Sources: https://www.drugbank.ca/drugs/DB08802
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/isothipendyl.html | https://www.ncbi.nlm.nih.gov/pubmed/22677929 | https://www.ncbi.nlm.nih.gov/pubmed/13792589 | https://www.ncbi.nlm.nih.gov/pubmed/14157559
Isothipendyl is a first generation H1 antagonist (antihistamine) and anticholinergic used as an antipruritic. It is nowadays scarcely used in the first line relief of allergies due to the anticholinergic side effect of somnolence but does have some limited use through topical application in the relief of insect bites and related itching (pruritus).
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4150325 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Calmogel Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 % single, topical Recommended |
unhealthy, 41 |
Disc. AE: Allergic contact dermatitis... AEs leading to discontinuation/dose reduction: Allergic contact dermatitis Sources: |
72 mg multiple, oral Studied dose |
unhealthy |
Disc. AE: Weakness generalised... AEs leading to discontinuation/dose reduction: Weakness generalised (1 patient) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Allergic contact dermatitis | Disc. AE | 1 % single, topical Recommended |
unhealthy, 41 |
| Weakness generalised | 1 patient Disc. AE |
72 mg multiple, oral Studied dose |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Bis[N,N-dimethyl-1-(10H-pyrido[3,2-b][1,4]benzothia-zin-10-yl)propan-2-aminium] tetrakis-(thio-cyanato-κN)cobaltate(II). | 2010-06-16 |
|
| Spectrophotometric studies on the investigation of chromium in environmental samples. | 2003-01 |
|
| Spectrophotometric determination of molybdenum(VI) using isothipendyl hydrochloride and pipazethate hydrochloride in alloy steels and soil samples. | 2001-09 |
|
| Phototoxic and photoprotective effects of topical isothipendyl. | 1995-04 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13792589
The dosage of isothipendyl in children was 6 to 8 mg. daily given as a syrup containing 2 mg. per teaspoonful. In adults the dosage varied from one 4 mg. tablet thrice daily to two 12 mg. sustained-action tablets thrice daily
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:46:45 GMT 2025
by
admin
on
Mon Mar 31 17:46:45 GMT 2025
|
| Record UNII |
953AP1LBV8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m6543
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
169186
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
235726
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL2111066
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
214-957-9
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
DBSALT000907
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
14668
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
1225-60-1
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
SUB02807MIG
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
953AP1LBV8
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
DTXSID1046845
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
C008214
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
100000088204
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY | |||
|
34433-15-3
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C76063
Created by
admin on Mon Mar 31 17:46:45 GMT 2025 , Edited by admin on Mon Mar 31 17:46:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |